Immunotherapy with dendritic cells loaded with glioblastoma stem cells: from preclinical to clinical studies

Cancer Immunology, Immunotherapy

Volumn 65, Issue 1, 2016, Pages 101-109

  Finocchiaro, Gaetano ^a   Pellegatta, Serena ^a  

^a DEPARTMENT OF NEUROSURGERY   (Italy)

Author keywords

Cancer stem like cells; Dendritic cells; Glioblastoma; Immunotherapy; NIBIT 2014

Indexed keywords

DENDRITIC CELL; GLIOBLASTOMA; HUMAN; IMMUNOLOGY; IMMUNOTHERAPY; PATHOLOGY; PROCEDURES; STEM CELL;

DENDRITIC CELLS; GLIOBLASTOMA; HUMANS; IMMUNOTHERAPY; STEM CELLS;

EID: 84953368236     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-015-1754-9     Document Type: Review

References (75)

1. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144:646–674. doi:10.1016/j.cell.2011.02.013
2. Schreiber RD, Old LJ, Smyth MJ (2011) Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion. Science 331:1565–1570. doi:10.1126/science.1203486
3. Rosenberg SA, Yang JC, Restifo NP (2004) Cancer immunotherapy: moving beyond current vaccines. Nat Med 10:909–915. doi:10.1038/nm1100
4. Siesjö P, Visse E, Sjögren HO (1996) Cure of established, intracerebral rat gliomas induced by therapeutic immunizations with tumor cells and purified APC or adjuvant IFN-gamma treatment. J Immunother Emphas Tumor Immunol 19:334–345
5. Liau LM, Black KL, Prins RM et al (1999) Treatment of intracranial gliomas with bone marrow-derived dendritic cells pulsed with tumor antigens. J Neurosurg 90:1115–1124. doi:10.3171/jns.1999.90.6.1115
6. Witham TF, Erff ML, Okada H et al (2002) 7-Hydroxystaurosporine-induced apoptosis in 9L glioma cells provides an effective antigen source for dendritic cells and yields a potent vaccine strategy in an intracranial glioma model. Neurosurgery 50(6):1327–1335
7. Akasaki Y, Kikuchi T, Homma S et al (2001) Antitumor effect of immunizations with fusions of dendritic and glioma cells in a mouse brain tumor model. J Immunother 24:106–113
8. Heimberger AB, Crotty LE, Archer GE et al (2000) Bone marrow-derived dendritic cells pulsed with tumor homogenate induce immunity against syngeneic intracerebral glioma. J Neuroimmunol 103:16–25
9. Insug O, Ku G, Ertl HC, Blaszczyk-Thurin M (2002) A dendritic cell vaccine induces protective immunity to intracranial growth of glioma. Anticancer Res 22:613–621
10. Kikuchi T, Akasaki Y, Abe T, Ohno T (2002) Intratumoral injection of dendritic and irradiated glioma cells induces anti-tumor effects in a mouse brain tumor model. Cancer Immunol Immunother 51:424–430
11. Ni HT, Spellman SR, Jean WC et al (2001) Immunization with dendritic cells pulsed with tumor extract increases survival of mice bearing intracranial gliomas. J Neurooncol 51:1–9
12. Okada H, Tahara H, Shurin MR et al (1998) Bone marrow-derived dendritic cells pulsed with a tumor-specific peptide elicit effective anti-tumor immunity against intracranial neoplasms. Int J Cancer 78:196–201
13. Pellegatta S, Finocchiaro G (2005) Cell therapies in neuro-oncology. Neurol Sci 26(Suppl 1):S43–S45. doi:10.1007/s10072-005-0405-x
14. Pellegatta S, Poliani PL, Corno D et al (2006) Dendritic cells pulsed with glioma lysates induce immunity against syngeneic intracranial gliomas and increase survival of tumor-bearing mice. Neurol Res 28:527–531. doi:10.1179/016164106X116809
15. De Vleeschouwer S, Van Calenbergh F, Demaerel P et al (2004) Transient local response and persistent tumor control in a child with recurrent malignant glioma: treatment with combination therapy including dendritic cell therapy. Case report. J Neurosurg 100:492–497
16. Rutkowski S, De Vleeschouwer S, Kaempgen E et al (2004) Surgery and adjuvant dendritic cell-based tumour vaccination for patients with relapsed malignant glioma, a feasibility study. Br J Cancer 91:1656–1662
17. Wheeler CJ, Das A, Liu G et al (2004) Clinical responsiveness of glioblastoma multiforme to chemotherapy after vaccination. Clin Cancer Res 10:5316–5326
18. Yamanaka R, Abe T, Yajima N et al (2003) Vaccination of recurrent glioma patients with tumour lysate-pulsed dendritic cells elicits immune responses: results of a clinical phase I/II trial. Br J Cancer 89:1172–1179
19. Yamanaka R, Homma J, Yajima N et al (2005) Clinical evaluation of dendritic cell vaccination for patients with recurrent glioma: results of a clinical phase I/II trial. Clin Cancer Res 11:4160–4167. doi:10.1158/1078-0432.CCR-05-0120
20. Yu JS, Liu G, Ying H et al (2004) Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma. Cancer Res 64:4973–4979. doi:10.1158/0008-5472.CAN-03-3505
21. Yamanaka R, Homma J, Yajima N et al (2005) Clinical evaluation of dendritic cell vaccination for patients with recurrent glioma: results of a clinical phase I/II trial. Clin Cancer Res 11:4160–4167. doi:10.1158/1078-0432.CCR-05-0120
22. Liau LM, Prins RM, Kiertscher SM et al (2005) Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment. Clin Cancer Res 11:5515–5525. doi:10.1158/1078-0432.CCR-05-0464
23. Polyzoidis S, Ashkan K (2014) Dendritic cell immunotherapy for glioblastoma. Expert Rev Anticancer Ther 14:761–763. doi:10.1586/14737140.2014.921571
24. Anguille S, Smits EL, Lion E et al (2014) Clinical use of dendritic cells for cancer therapy. Lancet Oncol 15:e257–e267. doi:10.1016/S1470-2045(13)70585-0
25. Finocchiaro G, Pellegatta S (2014) Perspectives for immunotherapy in glioblastoma treatment. Curr Opin Oncol 26(6):608–614. doi:10.1097/CCO.0000000000000135
26. Lasky JL, Panosyan EH, Plant A et al (2013) Autologous tumor lysate-pulsed dendritic cell immunotherapy for pediatric patients with newly diagnosed or recurrent high-grade gliomas. Anticancer Res 33:2047–2056
27. Pellegatta S, Eoli M, Frigerio S et al (2013) The natural killer cell response and tumor debulking are associated with prolonged survival in recurrent glioblastoma patients receiving dendritic cells loaded with autologous tumor lysates. Oncoimmunology 2:e23401. doi:10.4161/onci.23401
28. Zitvogel L, Apetoh L, Ghiringhelli F, Kroemer G (2008) Immunological aspects of cancer chemotherapy. Nat Rev Immunol 8:59–73. doi:10.1038/nri2216
29. Galluzzi L, Senovilla L, Zitvogel L, Kroemer G (2012) The secret ally: immunostimulation by anticancer drugs. Nat Rev Drug Discov 11:215–233. doi:10.1038/nrd3626
30. Sampson JH, Aldape KD, Archer GE et al (2011) Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma. Neuro Oncol 13:324–333. doi:10.1093/neuonc/noq157
31. Eoli M, Pellegatta S, Frigerio S et al (2014) Association of increased progression-free survival in primary glioblastomas with lymphopenia at baseline and activation of NK and NKT cells after dendritic cell immunotherapy. In: ASCO Annual Meeting. J Clin Oncol 32:5 (suppl; abstr 2087)
32. Pellegatta S, Eoli M, Cantini G et al (2014) P02.03 * Increased count of NK and NKT cells are associated with prolonged survival in primary glioblastoma patients treated with dendritic cell immunotherapy in combination with radio- and chemo-therapy. Neuro Oncol 16:ii33. doi:10.1093/neuonc/nou174.119(poster)
33. Singh SK, Hawkins C, Clarke ID et al (2004) Identification of human brain tumour initiating cells. Nature 432:396–401. doi:10.1038/nature03128
34. Quintana E, Shackleton M, Sabel MS et al (2008) Efficient tumour formation by single human melanoma cells. Nature 456:593–598. doi:10.1038/nature07567
35. Beier D, Hau P, Proescholdt M et al (2007) CD133(+) and CD133(-) glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles. Cancer Res 67:4010–4015. doi:10.1158/0008-5472.CAN-06-4180
36. Ben-Porath I, Thomson MW, Carey VJ et al (2008) An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat Genet 40:499–507. doi:10.1038/ng.127
37. Chen R, Nishimura MC, Bumbaca SM et al (2010) A hierarchy of self-renewing tumor-initiating cell types in glioblastoma. Cancer Cell 17:362–375. doi:10.1016/j.ccr.2009.12.049
38. Pellegatta S, Poliani PL, Corno D et al (2006) Neurospheres enriched in cancer stem-like cells are highly effective in eliciting a dendritic cell-mediated immune response against malignant gliomas. Cancer Res 66:10247–10252. doi:10.1158/0008-5472.CAN-06-2048
39. Ghods AJ, Irvin D, Liu G et al (2007) Spheres isolated from 9L gliosarcoma rat cell line possess chemoresistant and aggressive cancer stem-like cells. Stem Cells 25:1645–1653. doi:10.1634/stemcells.2006-0624
40. Singh SK, Clarke ID, Terasaki M et al (2003) Identification of a cancer stem cell in human brain tumors. Cancer Res 63:5821–5828
41. Tunici P, Bissola L, Lualdi E et al (2004) Genetic alterations and in vivo tumorigenicity of neurospheres derived from an adult glioblastoma. Mol Cancer 3:25. doi:10.1186/1476-4598-3-25
42. Lee J, Kotliarova S, Kotliarov Y et al (2006) Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell 9:391–403. doi:10.1016/j.ccr.2006.03.030
43. Verhaak RGW, Hoadley KA, Purdom E et al (2010) Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17:98–110. doi:10.1016/j.ccr.2009.12.020
44. Soeda A, Park M, Lee D et al (2009) Hypoxia promotes expansion of the CD133-positive glioma stem cells through activation of HIF-1alpha. Oncogene 28:3949–3959. doi:10.1038/onc.2009.252
45. Bhat KPL, Balasubramaniyan V, Vaillant B et al (2013) Mesenchymal differentiation mediated by NF-κB promotes radiation resistance in glioblastoma. Cancer Cell 24:331–346. doi:10.1016/j.ccr.2013.08.001
46. Sottoriva A, Spiteri I, Piccirillo SGM et al (2013) Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics. Proc Natl Acad Sci USA 110:4009–4014. doi:10.1073/pnas.1219747110
47. Bonavia R, Inda M-M, Cavenee WK, Furnari FB (2011) Heterogeneity maintenance in glioblastoma: a social network. Cancer Res 71:4055–4060. doi:10.1158/0008-5472.CAN-11-0153
48. Reardon DA (2015) Wen PY (2015) Glioma in 2014: unravelling tumour heterogeneity-implications for therapy. Nat Rev Clin Oncol 12(2):69–70. doi:10.1038/nrclinonc.2014.223
49. Stieber D, Golebiewska A, Evers L et al (2014) Glioblastomas are composed of genetically divergent clones with distinct tumourigenic potential and variable stem cell-associated phenotypes. Acta Neuropathol 127:203–219. doi:10.1007/s00401-013-1196-4
50. Di Tomaso T, Mazzoleni S, Wang E et al (2010) Immunobiological characterization of cancer stem cells isolated from glioblastoma patients. Clin Cancer Res 16:800–813. doi:10.1158/1078-0432.CCR-09-2730
51. Wei J, Barr J, Kong L-Y et al (2010) Glioblastoma cancer-initiating cells inhibit T-cell proliferation and effector responses by the signal transducers and activators of transcription 3 pathway. Mol Cancer Ther 9:67–78. doi:10.1158/1535-7163.MCT-09-0734
52. Wei J, Wu A, Kong L-Y et al (2011) Hypoxia potentiates glioma-mediated immunosuppression. PLoS One 6:e16195. doi:10.1371/journal.pone.0016195
53. Wu A, Wei J, Kong L-Y et al (2010) Glioma cancer stem cells induce immunosuppressive macrophages/microglia. Neuro Oncol 12:1113–1125. doi:10.1093/neuonc/noq082
54. Alizadeh D, Zhang L, Brown CE et al (2010) Induction of anti-glioma natural killer cell response following multiple low-dose intracerebral CpG therapy. Clin Cancer Res 16:3399–3408. doi:10.1158/1078-0432.CCR-09-3087
55. Castriconi R, Daga A, Dondero A et al (2009) NK cells recognize and kill human glioblastoma cells with stem cell-like properties. J Immunol 182:3530–3539. doi:10.4049/jimmunol.0802845
56. Brown CE, Starr R, Martinez C et al (2009) Recognition and killing of brain tumor stem-like initiating cells by CD8+ cytolytic T cells. Cancer Res 69:8886–8893. doi:10.1158/0008-5472.CAN-09-2687
57. Pallini R, Ricci-Vitiani L, Banna GL et al (2008) Cancer stem cell analysis and clinical outcome in patients with glioblastoma multiforme. Clin Cancer Res 14:8205–8212. doi:10.1158/1078-0432.CCR-08-0644
58. De Bacco F, Casanova E, Medico E et al (2012) The MET oncogene is a functional marker of a glioblastoma stem cell subtype. Cancer Res 72:4537–4550. doi:10.1158/0008-5472.CAN-11-3490
59. Sampson JH, Heimberger AB, Archer GE et al (2010) Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. J Clin Oncol 28:4722–4729. doi:10.1200/JCO.2010.28.6963
60. Xu Q, Liu G, Yuan X et al (2009) Antigen-specific T-cell response from dendritic cell vaccination using cancer stem-like cell-associated antigens. Stem Cells 27:1734–1740. doi:10.1002/stem.102
61. De Rosa A, Pellegatta S, Rossi M et al (2012) A radial glia gene marker, fatty acid binding protein 7 (FABP7), is involved in proliferation and invasion of glioblastoma cells. PLoS One 7:e52113. doi:10.1371/journal.pone.0052113
62. Cantini G, Pisati F, Pessina S et al (2012) Immunotherapy against the radial glia marker GLAST effectively triggers specific antitumor effectors without autoimmunity. Oncoimmunology 1:884–893. doi:10.4161/onci.20637
63. Favaro R, Appolloni I, Pellegatta S et al (2014) SOX2 is required to maintain cancer stem cells in a mouse model of high-grade oligodendroglioma. Cancer Res 74:1833–1844. doi:10.1158/0008-5472.CAN-13-1942
64. Park D, Xiang AP, Mao FF et al (2010) Nestin is required for the proper self-renewal of neural stem cells. Stem Cells 28:2162–2171. doi:10.1002/stem.541
65. Mehta S, Huillard E, Kesari S et al (2011) The central nervous system-restricted transcription factor Olig2 opposes p53 responses to genotoxic damage in neural progenitors and malignant glioma. Cancer Cell 19:359–371. doi:10.1016/j.ccr.2011.01.035
66. Vik-Mo EO, Nyakas M, Mikkelsen BV et al (2013) Therapeutic vaccination against autologous cancer stem cells with mRNA-transfected dendritic cells in patients with glioblastoma. Cancer Immunol Immunother 62:1499–1509. doi:10.1007/s00262-013-1453-3
67. Ignatova TN, Kukekov VG, Laywell ED et al (2002) Human cortical glial tumors contain neural stem-like cells expressing astroglial and neuronal markers in vitro. Glia 39:193–206. doi:10.1002/glia.10094
68. Phuphanich S, Wheeler CJ, Rudnick JD et al (2013) Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients with newly diagnosed glioblastoma. Cancer Immunol Immunother 62:125–135. doi:10.1007/s00262-012-1319-0
69. Orzan F, Pellegatta S, Poliani PL et al (2011) Enhancer of Zeste 2 (EZH2) is up-regulated in malignant gliomas and in glioma stem-like cells. Neuropathol Appl Neurobiol 37:381–394. doi:10.1111/j.1365-2990.2010.01132.x
70. Speranza MC, Frattini V, Pisati F et al (2012) NEDD9, a novel target of miR-145, increases the invasiveness of glioblastoma. Abstract 3:723–734
71. Frattini V, Pisati F, Speranza MC et al (2012) FOXP3, a novel glioblastoma proliferation and migration affects. Abstract 3:1146–1157
72. Patanè M, Porrati P, Bottega E et al (2013) Frequency of NFKBIA deletions is low in glioblastomas and skewed in glioblastoma neurospheres. Mol Cancer 12:160. doi:10.1186/1476-4598-12-160
73. Nava S, Dossena M, Pogliani S et al (2012) An optimized method for manufacturing a clinical scale dendritic cell-based vaccine for the treatment of glioblastoma. PLoS One 7:e52301. doi:10.1371/journal.pone.0052301
74. Parsons DW, Jones S, Zhang X et al (2008) An integrated genomic analysis of human glioblastoma multiforme. Science 321:1807–1812. doi:10.1126/science.1164382
75. Kim H, Zheng S, Amini SS et al (2015) Whole-genome and multisector exome sequencing of primary and post-treatment glioblastoma reveals patterns of tumor evolution. Genome Res 25(3):316–327. doi:10.1101/gr.180612.114